propria and connective tissue. Penetration of microbes triggers strong innate immune responses by pathogen recognition receptors on epithelial cells and immune cells, such as macrophages, innate lymphoid cells, and mast cells, residing among epithelial cells or on the basolateral side of the lamina reticularis. Subsequent sensitization and activation of adaptive immune responses can result, including type 2 immune responses of relevance to the allergic diathesis. Epithelial function can become compromised by alterations in numerous key functional or structural elements, such as epithelial junctional or filamentous proteins. Loss of protective anti-proteases, antimicrobial peptides or compounds, or disturbances in transport of ions, protons or water can also disrupt barrier function. Profound activation of sensory nerves important in manifestation of disease experienced by the patient is also associated with loss of barrier and sensitization. In this section we briefly discuss some of the salient mechanisms and features of barrier loss commonly shared by all patients with allergic diseases (summarized in Fig 1) .
Atopic dermatitis
Atopic dermatitis (AD) is characterized by loss of barrier function of the skin, culminating in a clinical phenotype characterized by formation of skin lesions. Skin barrier dysfunction is induced by disruption of the stratum corneum, a dense protein-lipid matrix that functions as a barrier to water loss, environmental insults and allergens. Filaggrin (FLG), a filament-associated epidermal differentiation complex (EDC) protein essential for regulation of epidermal homeostasis, is highly deficient in the skin of many patients with AD. 1 Similarly, the FLG-like proteins hornerin and FLG2 are detected at FIG 1 . Key features of epithelial dysfunction common to all allergic disease. Epithelial barriers predisposed to type 2 allergic disease are characterized by increased permeability and aberrant behavior of morphogenetic programs that maintain epithelial homeostasis. Both exogenous (inhaled allergens, respiratory viruses, chemical sensitizers, and air pollutants) and endogenous (hormones, dietary factors, and altered circadian clock) disruptors of epithelial homeostasis can drive predisposition to allergic sensitization by altering homeostatic activity of developmental pathways (WNT, Notch, and Hedgehog) that maintain proper epithelial-to-mesenchymal communication, epithelial differentiation, and barrier integrity. Transition to a remodeling state in disease typically follows allergic sensitization and inflammatory responses. This transition features further loss of differentiation signals, downregulation of innate defense molecules, profibrotic processes, deposition of extracellular matrix, and potentiated activity of the mesenchymal unit. ILC2, Group 2 innate lymphoid cell; TSLP, thymic stromal lymphopoietin.
significantly lower levels in the skin of many patients with AD, irrespective of FLG genotype. 2 Dysregulated FLG is frequently discussed as central to the origins of disease 3 ; however, barrier defects in patients with AD go far beyond FLG deficiency. Defects in claudins 1, 4, and 8 have also been associated with the development of AD. [4] [5] [6] [7] Disruption of the skin barrier involves defects in the entire keratinocyte terminal differentiation program through dysregulation of multiple EDC genes on human chromosome region 1q21, 8 reduced expression of epithelial tight junction proteins, 9 increased transepidermal water loss, 10, 11 and reduction in epidermal natural moisturizing factors. 12 The impaired skin barrier function in patients with AD also involves altered lipid profiles, including shortening of carbon chain length of stratum corneum lipids (ceramides and free fatty acids), an event that exhibits strong correlations with transepidermal water loss and occurs independently of FLG mutations. [13] [14] [15] [16] Intriguingly, clinically unaffected nonlesional skin in patients with AD similarly exhibits defects in terminal keratinocyte differentiation, 17 as well as reduced FLG and lipid levels, 14, 15 suggesting a global cutaneous predisposition to barrier dysfunction in patients with AD.
Asthma
An intact functional mucosal barrier is crucial for maintenance of airway homeostasis. Despite the existence of multiple clinical endotypes, patients with most forms of asthma exhibit a dysregulated epithelial barrier. Asthmatic epithelium is characterized by an increase in basal and goblet cell counts 18 and a decrease in terminally differentiated ciliated cell counts that are frequently accompanied by basement membrane thickening 19, 20 and epithelial shedding, with the formation of Creola bodies consisting of clusters of shed epithelium (even in patients with mild forms of the disease). [21] [22] [23] Disruption of epithelial tight and adherens junctions is typical for asthma, with marked loss of E-cadherin 24 and claudin-18. 25 The underlying extracellular matrix, which supports homeostasis and repair of the epithelium, also undergoes significant remodeling, which is characterized by increased deposition of provisional matrix components, such as the glycoproteins fibronectin, 26 periostin, 27 tenascin-C, 28, 29 hyaluronan, and versican. 30 Epithelial-to-mesenchymal transition (EMT) was proposed as a mechanism underlying epithelial dedifferentiation and perpetuated remodeling 31 ; however, this remains a topic of debate because of the lack of markers accurately defining this process in asthmatic patients. 32 Mucociliary clearance, which depends on cooperation between submucosal glands, goblet cells, and ciliated cells, and normal chemical barrier function of the asthmatic epithelium are also compromised. There are profound changes in relative proportions and viscosity of mucins MUC5AC and MUC5B, which in turn contribute to airway obstruction 33, 34 and downregulation of lipoxins. 35 Perturbations in sphingolipid balance with increased levels of ceramides have also been reported in airway epithelium of asthmatic patients. 36 
Allergic rhinitis
Mucosal epithelial barrier disruption is observed in both models of allergic rhinitis and in patients. 37 Allergens can contain proteases and have been shown to disrupt epithelial tight junctions. 38, 39 Nasal challenge with histamine or antigen in a sensitized subject can cause significant plasma exudation across the epithelial barrier. This is a nondestructive process and might be a first-line defense of the respiratory mucosa. 40 A proteomic study detected changes reflecting altered epithelial permeability in patients with allergic rhinitis, including increased a 2 -macroglobulin levels, a measure of vascular and epithelial leak, and decreased levels of the protective antileukoproteinase secretory leukocyte peptidase inhibitor. 41 Reduced levels of the barrier proteins E-cadherin and zonula occludens 1 (ZO-1) were observed in nasal mucosal tissue from patients with allergic rhinitis compared with those in healthy control subjects by using real-time PCR, Western blotting, and immunohistochemistry. 42 In vitro IL-4 and TNF induced loss of these markers in the epithelium. Steelant et al 43 observed decreased barrier function measured in vitro by using primary epithelial cells collected in patients with allergic rhinitis compared with healthy control subjects and found decreased expression of the tight junction proteins occludin and ZO-1.
Chronic rhinosinusitis
Early studies provided evidence for a defective barrier in patients with chronic rhinosinusitis (CRS) by using immunohistochemistry, bioelectric evaluation, and ion transport function as indicators. 44, 45 Using air-liquid interface epithelial cultures, Soyka et al 46 showed reduced barrier function in tissues collected from patients with or without CRS. A number of studies have focused on loss of epithelial tight junctions in patients with CRS by assessing levels of individual tight junction proteins. 37, 47 Alterations of the expression of ZO-1 and E-cadherin were reported by Jang et al. 48 Epithelial damage, including shortening of desmosomes, was reported by Shahana et al 49 in a study using electron microscopy in polyp tissue derived from asthmatic patients. Reductions in levels of the tight junction proteins claudin-1 and occludin in tissues from patients with CRS were reported in another study. 50 Meng et al 51 reported that ZO-1, occludin, and E-cadherin levels were all reduced in mature polyps removed from patients with CRS with nasal polyps. Moreover, aquaporin 5, a marker of epithelial differentiation, was significantly reduced in sinonasal samples of patients with CRS with nasal polyps compared with levels in those with CRS without nasal polyps or control subjects. 52 Physical evidence of disruption of epithelial barrier in patients with CRS includes prominent acanthosis and acantholysis. 47 The loss of differentiation and acanthosis might result from a cycle of ongoing injury and repair associated with EMT. Factors that have been identified in tissues from patients with CRS that might stimulate barrier loss and acanthosis include TGF-a, oncostatin M, epiregulin, hypoxic activation of hypoxia-inducible factor 1a, and endocrine deficiency (see below).
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Eosinophilic esophagitis
The esophagus is composed of stratified squamous epithelium remarkably similar to the epithelium of the skin, only differing in its lack of a cornified layer and its possession of a mucous layer. 56 As occurs in patients with other type 2 diseases, the normal structure of the epithelium is disrupted in patients with eosinophilic esophagitis (EoE), including basal cell hyperplasia, dilated intracellular spaces, and impaired barrier function and cell junctions. 57, 58 These changes are thought to be associated with dysregulated epithelial differentiation and impaired epithelial barrier formation. As in the skin, the epithelium in patients with EoE is characterized by dysregulation of genes of the EDC on human chromosome 1q21, including FLG, involucrin, and several small proline-rich repeat family members. 59 In esophageal epithelial cells, FLG was shown to be negatively regulated in response to IL-13 ex vivo.
59 Levels of the desmosomal and tight junctional proteins desmoglein-1, E-cadherin, and claudin-1 are reduced in patients with active EoE. 60, 61 Epithelial barriers in patients with EoE also exhibit characteristic features of EMT, which correlate with subepithelial fibrosis and eosinophil counts in human biopsy specimens. 62 
MECHANISMS OF BARRIER DEFECTS Introduction
Barrier defects can be induced by loss or defects in key proteins that comprise tight or adherens junctions, disruption of barrier by environmental exposures (including proteases, chemical injury or trauma), inflammatory responses that induce barrier-disrupting T H 2 cytokines, and endogenous mechanisms, such as altered central metabolism and imbalance of hormones that regulate epithelial homeostasis. The purpose of this section is to briefly consider some of the external and internal factors thought to be of particular importance in disruption of barriers in patients with allergic diseases.
Genetic and epigenetic barrier defects
Genome-wide association studies and positional cloning have successfully identified several risk alleles and loci reproducibly associated with AD, asthma, and EoE. Interestingly, many allergic susceptibility candidate genes control epithelial barrier homeostasis. Null gene mutations of FLG (as mentioned previously, an important component of terminal keratinocyte differentiation) are the most significant known risk factors for AD and EoE, along with mutations of other EDC genes. 59 Polymorphisms in the asthma susceptibility genes ORMDL3, GSDMB, PCDH1, CDHR3, ADAM33, SMAD3, IL1RL1, and IL18R1 are now thought to be linked to aberrant epithelial remodeling, the unfolded protein response, and lipid biosynthesis. [63] [64] [65] A recent pathway-based association study by Barreto-Luis et al 66 revealed novel asthma susceptibility loci near WNT pathway genes that regulate barrier morphogenesis.
Even though genetic associations are stronger within clinically well-defined subgroups of disease, 67 overall allergic diseaseassociated alleles typically have small effect sizes and cannot account for the rapidly increasing prevalence of allergy, 68 reinforcing the significance of environmental factors in development of allergic diseases. Significantly, environmental inputs can affect gene transcription through heritable epigenetic regulation that does not require alterations in gene sequences, including DNA and histone modifications, as well as changes in noncoding RNAs. 69 One of the notable epigenetic changes in asthmatic epithelium involves hypomethylation of KRT5, 69 which increases keratin 5 expression in basal epithelium and can therefore lead to dysregulated epithelial differentiation. [70] [71] [72] The potential for epigenetic ''reprogramming'' is evident when asthmatic epithelium cultured in normal medium still retains persistent indicators of defects in junctional maintenance, ''immaturity,'' and repair ex vivo. 73 The topic of epigenetic mechanisms of epithelial remodeling is a still-emerging area of investigation of epithelial barrier dysfunction, and ongoing work is likely to produce novel insights into aberrant regulation of epithelial differentiation programs in patients with allergic disease.
Environmental contributions to barrier loss
Barriers of the skin, airways, and gastrointestinal tract constantly experience biological and chemical insults from the surrounding environment. Allergens, such as house dust mite or pollens, are capable of disrupting the physical integrity of the barrier through their protease activity, which degrades adhesion proteins and triggers the epithelial alarmin cytokine response. [74] [75] [76] [77] [78] Respiratory viruses promote airway epithelial barrier dysfunction by disrupting epithelial junctions, which might represent an inciting or sustaining event linking viral infections and allergic inflammation. 79, 80 Interestingly, the asthma susceptibility barrier gene CDHR3 is a receptor for rhinovirus C. 65 Many chemicals and irritants prevalent in industrial environments act as adjuvants and sensitizers, disrupting normal functions of the epithelial barrier, setting off alarmin responses, and promoting allergic sensitization. 81, 82 Air pollution associates with the development of AD in both children and adults. 83, 84 Less obvious but equally important environmental contributors to barrier loss do not disrupt barrier externally but act as endogenous factors in dysregulation of epithelial homeostatic processes. Stimulation of the aryl hydrocarbon receptor by ingested or inhaled xenobiotics, such as polycyclic aromatic hydrocarbons, is now known to affect epidermal differentiation and skin barrier formation. 85 Xenoestrogens linked to development of allergy, such as bisphenols and phthalates, mimic the natural action of nuclear hormonal receptor ligands (estrogens and androgens) and thus disrupt normal epithelial homeostatic processes. [86] [87] [88] A multitude of dietary factors have the capacity to alter epithelial behavior through direct receptor action or indirect regulation of tissue metabolism. For example, Fischer et al 89 demonstrated that vitamin D supplementation, acting through the vitamin D receptor pathway, reduces EMT processes and improves barrier function in several clinically relevant murine models of asthma. Fatty acid-deficient diets spontaneously induce skin barrier disruption through alteration of skin metabolism. 90, 91 Moreover, the intestinal microbiome is now emerging as an important regulator of the metabolism with consequences for epithelial and immune homeostasis. 92 
Defects in hormonal signaling as early events
Contributions of biological systems other than the immune system to disruption of epithelial homeostasis and priming of allergic response are currently poorly understood. Several studies report insulin resistance in children and adults with asthma, 93, 94 as well as association of asthma and atopic eczema with prediabetes and metabolic syndrome. 95 We found profound changes in serum hormonal profiles of prepubertal nonobese allergic children compared with nonallergic control subjects, as well as patients with CRS compared with healthy control subjects, including decreased levels of serum insulin and increased output of thyroid and growth hormones. 96 Hormones play a critical role in the maintenance of epithelial barrier homeostasis and integrity through their integration with epithelial morphogenetic programs, 88, 97 as evidenced by deficiencies in wound healing and epithelial dysfunction in patients with thyroid disease and diabetes. 98, 99 Insulin and insulin-like growth factor 1 are essential drivers of epithelial differentiation and regulators of energy metabolism. Double-transgenic mice lacking both insulin and insulin-like growth factor 1 receptors are characterized by severe defects in epithelial differentiation, severely impaired stratification of the epidermis, spontaneous lesions, and overall loss of skin barrier function. 100 Recently, sex steroids and estrogen in particular are receiving more attention for their potential to explain sex bias in the prevalence of allergic disease. 101 Glucocorticoids have profound effects on epithelial differentiation 102, 103 and exemplify the therapeutic potential of manipulating the endocrine system in the treatment of allergic disease.
Disruption of normal epithelial development
The significance of early-life events in initiation and propagation of allergic disease is now widely recognized. The first 2 years of life represent a window of susceptibility for asthma development. Importantly, epithelial barriers in childhood are shaped and regulated by active ongoing developmental programs. In particular, morphogenesis of the lung epithelial barrier continues throughout normal postnatal development, as characterized by ongoing septation and epithelialization of the lung. 104 Consequently, perturbation of barrier morphogenesis in childhood can have a lasting effect on adult epithelium through alteration of developmental programs and epigenetic reprogramming at developmental checkpoints. [105] [106] [107] Multiple lines of evidence now implicate active re-engagement of morphogenetic programs in adult disease typically not seen in adult homeostatic tissue. [108] [109] [110] Alterations of the Wnt, 66 Hippo, 111 Notch/Jagged, 112, 113 and Hedgehog 114 developmental pathways all exhibit strong association with epithelial remodeling and allergy.
Early disruption of normal barrier development frequently predates atopy 11, 44 and is emerging as central to initiation of the atopic march. Mouse models of the atopic march demonstrate conclusively that sensitization to allergens through disrupted skin barriers is sufficient to elicit an immune response at other barrier sites. 115, 116 Causes of disruption of epithelial morphogenesis early in life are not well understood. Early-life viral exposures 117, 118 and changes in microbiota 119 are some of the better understood factors driving aberrant epithelial responses and a predisposition to allergic sensitization.
The injury-repair cycle and EMT
Exposure to environmental factors causes injury or disruption of normal homeostasis of the epithelium, followed by engagement of robust repair processes to minimize further damage from microbes and environment. Mature differentiated epithelial cells undergo EMT in which the cells lose their attachments to basement membrane and each other, lose their polarity, begin to divide, and become migratory to rapidly cover the injured area. During this process, epithelial cells lose expression of the tight junction proteins ZO-1, occludin, E-cadherin, and other markers of mature differentiated epithelium. The mesenchymal cells derived from the basal epithelial cells begin to produce desmin, fibronectin, tenascin, laminin, collagens, and other proteins that form a provisional matrix to protect the exposed basement membrane or lamina propria and express differentiation markers, such as a-smooth muscle actin. Evidence for EMT usually consists of loss of tight junction proteins, gain of provisional matrix proteins or biomarkers, or both. Early studies by Davies, Holgate, Hackett, Knight, and others found evidence for persistence of EMT in asthmatic patients, [120] [121] [122] [123] although it is more often described as a mild ''partial EMT'' phenotype, which could contribute to poor expression of conventional EMT markers in airways of asthmatic patients. 32 More recent studies found similar evidence for increased EMT in patients with allergic rhinitis. 42, 43 Several studies have demonstrated ongoing EMT in patients with CRS. 37, 47, [49] [50] [51] Two studies have demonstrated ongoing EMT in patients with EoE. 62, 124 However, to date, the authors have not found any reports of EMT (as classically defined by developmental biologists) in patients with AD, despite abundant evidence for loss of epithelial differentiation programs in the skin of patients with AD. Thus most chronic type 2 inflammatory diseases often appear to have a chronic EMT-based ongoing injury-repair cycle.
Inflammation and barrier: A vicious cycle
Whether inflammation is the primary cause of barrier disruption or whether it is barrier dysfunction that leads to sensitization and aberrant inflammatory response poses a long-standing ''chicken-egg'' dilemma (Fig 2) . Aberrant innate immune activity at barrier sites favors sensitization to innocuous antigens, and if there is an ensuing adaptive immune response, it can lead to a full-scale inflammatory attack on epithelial cells. During chronic inflammation associated with repeated or persistent antigen exposure, inflammation can lead to persistent disruption of epithelial junctions, as well as epithelial remodeling and subepithelial fibrosis driven by chronic perpetuated repair. Conversely, an accumulating body of evidence points to a causal role for barrier dysfunction as a primary driver of the allergic response and a vicious cycle of barrier leak. [125] [126] [127] Strikingly, only 30% to 40% of cases of allergic disease (asthma, eczema, and allergic rhinitis) in early childhood are attributable to atopy, and 60% to 70% of cases result from yet unknown factors. 128 In most atopic march cases, increased skin permeability at birth and nonatopic eczema frequently predate development of atopy, 11, 127 regardless of FLG mutations. 10 Moreover, although the atopic march assumes that one allergic disease brings risk of acquisition of another allergic disease later in life, it might involve sensitization to antigens different from those that triggered the initial disease. 129, 130 From this perspective, an alternative view might be that atopy and allergic inflammation are both secondary to a yet-unknown systemic process progressively afflicting epithelial barriers of the skin, gut, and airway.
Based on our observations of hormonal imbalance in allergic children (described above), we hypothesize that dysregulation of the endocrine system could represent a missing systemic link underlying susceptibility to initial barrier dysfunction. Remarkable similarities in the biology of barrier dysfunction across different allergic diseases (Fig 1) , including upper and lower ''unified'' airway responses and nonlesional defects in clinically unaffected skin of patients with AD, all support the existence of such a systemic trigger of disease. [131] [132] [133] Transgenic mouse models with defects in proteins maintaining epithelial homeostasis, such as FLG, are also characterized by spontaneous allergic sensitization and enhanced allergic inflammation. [134] [135] [136] [137] This notion of causality of a pre-existing barrier problem fits well with an emerging view of type 2 immunity as a ''restorative'' response evolved to maintain tissue homeostasis and assist with repair and remodeling. 138, 139 For example, Huang et al 140 provide supporting evidence suggesting that T H 2 immune responses and homeostatic eosinophil activity 141 might have evolved not to expel parasites but rather to remodel tissue that contains parasitic infestation and minimize potential damage to the host.
IDENTIFYING KEY DRIVERS OF DEFECTS AND THE BASIS FOR PREDISPOSITION TO BARRIER DISEASE
The existence of a dilemma about whether it is barrier loss or sensitization that is the primary cause of this vicious cycle illustrates well the complexity of allergic pathogenesis (Fig 2) . In healthy subjects multiple biological systems and processes must work in unison to maintain tissue homeostasis at barrier sites. This includes morphogenetic/developmental programs, metabolism, and the endocrine and immune systems. There is a growing list of molecules that we now believe are of critical importance in regulating barrier biology; however, despite exhibiting strong phenotypes in models of disease, they might not be central drivers of disease pathogenesis. FLG, for example, is only one of many molecules in the EDC. 142 Knockdown of FLG alone was not sufficient to affect lipid composition and permeability in an ex vivo skin model. 143 Several other EDC molecules play an equally critical role in epithelial homeostasis and are frequently downregulated with FLG in patients with AD independent of FLG genotype or atopic status. 8 Such changes in differentiation status of cells are intricately intertwined with changes in tissue metabolic demands, 144 aberrant immune responses, 145 and epigenetic rewiring. 146 The question then becomes which nongenetic factors have the capacity to dysregulate the entire EDC cluster, affecting the balance of the whole system. Identifying such central mediators is the key to finding strategies to restore the homeostatic state of the epithelial barrier. The endocrine system and changes in central metabolism have the potential to be central drivers of the predisposition to barrier defects, given the systemic regulatory effects of hormones (insulin and insulin-like growth factor 1 [IGF-1]) on epithelial morphogenetic programs of all barrier sites [147] [148] [149] and their regulatory roles for metabolism and immunity. Our understanding of central mediators of allergic disease is currently impeded by use of reductionist approaches and limited focus on processes of the immune system, insufficient understanding of complexity of biological interactions that control normal epithelial homeostasis, the dynamic nature of biological systems, and the extreme clinical heterogeneity of asthma and other allergic diseases. Studies of systems and integrative biology address exactly these challenges and are now emerging as critical in advancing all branches of biomedical science. Next-generation sequencing technology, shared availability of ''big data,'' and advances in computational biology are new promising tools for the discovery of novel drivers of barrier dysfunction.
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TARGETS FOR THERAPEUTIC INTERVENTION
There are severe forms of the diseases discussed in this review (ie, asthma, allergic rhinitis, CRS, EoE, and AD) that are difficult to manage and for which there is a serious unmet medical need for new and more effective medications. At present, one of the most highly effective classes of drugs for these diseases is topical glucocorticosteroids. These drugs improve elements of innate immunity, as well as barrier function, as measured based on a number of criteria, including markers of tight junction presence and function. Although the benefit of corticosteroids derives from suppressing the inflammatory response, such as expression of IL-13 and other cytokines, as well as direct effects on epithelial cells to promote barrier integrity, the relative contribution of these effects is not clear. New classes of drugs are rapidly emerging to help manage disease in patients for whom glucocorticosteroids are inadequate to control disease. This includes small-molecule drugs that block signaling pathways (eg, chemoattractant receptor-homologous molecule [CRTH2] expressed on T H 2 lymphocytes, GATA-3, Janus kinase, and other kinases) and mAbs that block cytokine signaling or eliminate key allergic effector cells, such as eosinophils and mast cells (eg, IL-5, IL-13, IL-5 receptor a, IL-4/IL-13 receptor a, and sialic acid-binding immunoglobulin-like lectin 8). The pursuit of barrier restorative therapies is another emerging field. 152 Based on the hypothesis advanced here that endocrine defects are important in disease pathogenesis, it will be worthwhile to test manipulation of signaling of other hormones (eg, insulin, growth hormone, and thyroid hormone) when seeking benefit for patients.
SUMMARY AND CONCLUSIONS
Many important questions remain to be answered regarding the mechanisms by which the epithelial barrier becomes disrupted in patients with allergic diseases. We also need to better understand the role that barrier loss plays as both an initiator and a consequence of the inflammatory process. We need to know more about genetic and epigenetic factors that cause barrier loss, as well as the environmental triggers and cellular and molecular mediators and targets of the process. Identifying the central mediators of the response and the consequences of barrier dysfunction in disease will be essential in building a rationale and in strategic design of new interventions to prevent or reverse the process.
